This bill adds a new federal offense to Title 18 that targets provision of medication (chemical) abortions outside an in-person clinical encounter. It requires a clinician to both examine the patient in person and be physically present where the drug is administered, and it requires scheduling a follow-up visit within 14 days; violations carry criminal penalties.
The text also defines who counts as a healthcare provider for purposes of the ban, protects patients from prosecution, and contains a narrow life‑saving exception and an ectopic‑treatment carve‑out.
The change is significant because it would directly constrain telehealth models that prescribe or mail abortion medications across state lines, reach into pharmacy dispensing and mail-order distribution where it can be shown to affect interstate commerce, and create a federal enforcement tool for a practice that has widely migrated online. Compliance officers, telehealth vendors, mail-order pharmacies, and clinicians who prescribe across state lines will need to reassess workflows, licensing, and risk exposure if this statute becomes law.
At a Glance
What It Does
The bill inserts 18 U.S.C. 1532 and makes it a federal crime for a licensed prescriber to provide or attempt to provide an abortion drug unless the prescriber has performed an in‑person exam, is physically present at the site of administration, and has scheduled a follow‑up within 14 days. It exempts life‑saving interventions and bars prosecution of patients.
Who It Affects
Out‑of‑state telemedicine clinicians and telehealth platforms that prescribe or arrange delivery of abortion medications, pharmacies and mail‑order distributors that dispense such medications across state lines, on‑site abortion clinics that compete with telehealth models, and patients who rely on remote care.
Why It Matters
By tying criminal liability to conduct 'in or affecting interstate or foreign commerce,' the bill reaches cross‑border telemedicine and distribution channels and shifts a policy debate about access into the federal criminal code. That creates immediate compliance, licensing, and operational questions for any provider that prescribes remotely.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a new federal criminal provision aimed specifically at medication abortion delivered without an in‑person clinical encounter. It does that by adding a new section to Title 18 that makes it unlawful for a clinician to dispense, prescribe, or otherwise make an abortion drug available unless three conditions are met: the clinician has physically examined the patient, the clinician is physically present at the location where the drug is used or administered, and the clinician schedules a follow‑up visit to assess the patient’s physical condition within 14 days.
The statute targets the provider’s conduct rather than the patient’s and includes a narrow exception where a chemical abortion is necessary to save the mother’s life.
The bill includes detailed definitions to govern enforcement. It defines ‘‘healthcare provider’’ as a person licensed to prescribe under applicable Federal and State law, and it defines ‘‘provide’’ broadly to include dispensing, prescribing, or otherwise making an abortion drug available.
The text also defines ‘‘abortion drug’’ and ‘‘chemical abortion’’ by reference to intent to terminate pregnancy, and it defines ‘‘unborn child’’ as beginning at fertilization. The statute expressly says it does not change treatment of verified ectopic pregnancies and includes a severability clause.Practically, the measure would affect a range of remote‑care practices: video consultations followed by mailing drugs, cross‑state teleprescribing, and pharmacy dispensing where the drug’s movement invokes interstate commerce.
Because the criminal prohibition hinges on the provider’s presence and the timing of follow‑up, organizations would need to redesign clinical pathways if they wanted to continue offering services without creating federal criminal exposure. The bill leaves open numerous operational questions—what counts as a physical exam, how courts will interpret ‘‘physically present,’’ and how intent in prescribing will be proved—so providers and compliance teams would confront legal uncertainty while deciding whether to change workflows.
The Five Things You Need to Know
The bill adds 18 U.S.C. 1532 as a federal offense specifically targeting chemical abortions provided without an in‑person exam, provider physical presence, and a scheduled follow‑up.
A violation is punishable by a fine of up to $1,000, imprisonment for up to 2 years, or both.
The statute requires scheduling a follow‑up visit to assess the patient’s physical condition within 14 days after administration or use of the abortion drug.
Subsection (b) bars prosecution of the patient who receives the abortion for violating this section or for conspiracy to violate it; criminal liability falls only on the provider.
The bill defines ‘unborn child’ to begin at fertilization and defines ‘abortion drug’ by the provider’s intent to terminate pregnancy, tying criminality to intent language.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name: the Teleabortion Prevention Act of 2025. This is purely captioning but signals the sponsor’s framing and legislative purpose for interpretive contexts.
Core criminal prohibition and exception
Creates the primary offense: a provider who knowingly provides or attempts to provide a chemical abortion in or affecting interstate or foreign commerce commits a crime unless three operative elements are met — an in‑person physical examination of the patient, the provider’s physical presence at the location of the abortion, and scheduling a follow‑up visit within 14 days. The subsection includes a life‑saving exception where the chemical abortion is necessary to save the mother’s life due to a physical disorder, illness, or injury related to pregnancy. Practically, this is the operative barrier to telemedicine models that do not include simultaneous, co‑located clinician supervision.
Patient immunity
Specifically precludes criminal prosecution of the patient for performing or receiving a chemical abortion under this section, or for conspiracy to violate it. That narrows enforcement targets to providers (and presumably their agents) and is likely intended to reduce the risk of prosecuting individuals who self‑manage care while preserving criminal penalties for clinicians and organizations that facilitate remote provision.
Definitions governing scope and proof
Sets definitions for key terms: ‘abortion drug,’ ‘attempts to provide,’ ‘healthcare provider,’ ‘provide,’ ‘chemical abortion,’ and ‘unborn child.’ Notable features: ‘healthcare provider’ is tied to state and federal prescribing licenses rather than a federal credential; ‘provide’ expressly covers dispensing and prescribing and any other means of making a drug available; and the definition of ‘abortion drug’ is outcome/intent‑driven (used to intentionally kill or terminate a pregnancy except to produce a live birth or remove a dead unborn child). Those choices will shape what prosecutable conduct looks like and how intent is established.
Ectopic treatment, severability, and technical changes
Carves out verified ectopic pregnancy treatment from any adverse construction and adds a severability clause to preserve remaining provisions if parts are invalidated. The bill also updates chapter headings and the table of sections in Title 18 to reflect the insertion of the new section and to rename the chapter heading. These are implementation details but the severability clause signals the drafters expect judicial review and want the statute to survive partial invalidation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- In‑person abortion clinics: Clinics that require face‑to‑face visits will face reduced competition from remote prescribers and mail‑order models, potentially preserving patient volume for brick‑and‑mortar providers.
- State enforcement authorities and regulators favoring in‑person care: The federal statute creates an additional legal tool to support state policies that restrict remote provision and can be used alongside state law where interstate commerce elements exist.
- Clinicians who already practice exclusively in‑person: Physicians and other prescribers who limit care to on‑site encounters avoid the compliance costs and criminal risk the bill imposes on remote prescribers.
Who Bears the Cost
- Telehealth abortion providers and telemedicine platforms: Organizations that rely on video visits, e‑consults, and mailing medications would need to suspend or redesign services that reach across state lines or expose clinicians to federal criminal liability.
- Pharmacies and mail‑order distributors: Pharmacies that dispense or ship abortion drugs across state borders could be entangled if doing so is treated as ‘providing’ under the statute, creating compliance and logistical burdens.
- Patients in rural or medically underserved areas: People who depend on remote care would face increased travel, potentially delayed care, and higher out‑of‑pocket costs if remote options are restricted.
- Insurers and health systems: Payers and systems that integrated teleabortion into care pathways might incur higher costs from redirected care, additional clinic visits, and administrative compliance measures.
Key Issues
The Core Tension
The bill embodies a direct trade‑off between an interest in ensuring in‑person clinical oversight of medication abortion and the competing interest in preserving access to remote reproductive healthcare: requiring physical presence may reduce certain clinical risks but simultaneously removes a low‑cost, lower‑barrier pathway for patients—especially in rural or restricted states—and transfers substantial compliance and criminal risk onto clinicians and distributing entities.
The bill reaches conduct tied to interstate commerce, which on its face gives federal prosecutors leverage over cross‑state telemedicine and shipping of drugs; however, proving an interstate commerce nexus in every case may require factual development (for example, showing the drug crossed state lines or that the provider’s activities used interstate communications). The statute’s reliance on intent‑based definitions (an ‘abortion drug’ as something used to ‘intentionally’ terminate pregnancy) raises evidentiary questions: prosecutors must prove the provider’s subjective intent, which could turn on medical records, communications, or testimony about the clinical rationale for treatment.
That creates both enforcement complexity and uncertain exposure for clinicians who treat early pregnancy complications where clinical intent is mixed.
Several operational ambiguities create practical compliance headaches. The statute does not define ‘‘physically examining’’ or ‘‘physically present at the location,’’ so providers lack a clear, standardized checklist for meeting the statute’s elements; telehealth vendors and clinicians will have to choose risk tolerances without authoritative guidance.
The narrow life‑saving exception and the explicit ectopic carve‑out reduce some emergency‑care fears, but the law’s language may still chill clinicians from treating miscarriages or providing pregnancy‑related pharmacologic care when the line between treatment and termination is not clinically distinct. Finally, the statutory choice to criminalize provider conduct rather than impose a civil regulatory penalty changes the stakes for compliance: even relatively modest fines and short prison terms carry outsized professional and reputational costs for clinicians and organizations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.